PDCD1 and cancer: In this context, anti-TIM3 antibodies, including Sym023, cobolimab, LY3321367, BGB-A425, and MBG453, in combination with several anti-PD-1/PD-L1 antibodies, are under clinical investigation for their efficacy against various cancers.